You are here

Article Text

Article menu
Download PDFPDF
ePoster
EP642 Combined programmed cell death ligand 1 (PD-L1)/CD8 expression in grade 3 endometrial carcinomas
  1. S Vagios1,
  2. P Yiannou2,
  3. E Giannikaki3,
  4. T Doulgeraki2,
  5. C Papadimitriou4,
  6. A Rodolakis5,
  7. A Nonni1,
  8. A Vlachos6 and
  9. K Pavlakis1,2
  1. 1Pathology Department, National and Kapodistrian University of Athens
  2. 2Pathology Department, IASO Women’s Hospital, Athens
  3. 3Pathology Department, Venizeleio-Pananeio General Hospital, Heraklion
  4. 4Oncology Unit, Aretaieion Hospital
  5. 51st Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens
  6. 6Department of Gynecological Oncology, IASO Women’s Hospital, Athens, Greece

Abstract

Introduction/Background The purpose of this study is to evaluate the combined immunohistochemical expression of programmed cell death ligand 1 (PD-L1) and CD8 in high-grade endometrial carcinomas and relate it to several clinicopathological parameters.

Methodology One hundred and one (101) surgically staged patients with high grade endometrial carcinomas (46.7% endometrioid and 53.5% non-endometrioid) were included in the study. PD-L1 and intraepithelial CD8 expression was evaluated by immunohistochemistry. PD-L1 expression was considered positive when ≥1% of membranous staining was identified. CD8 expression was considered high when the number of CD8+ intraepithelial cells per high-power field (HPF) was equal to or above the median CD8+ cell count (17.6 cells)/HPF. Four groups of tumors were isolated: group 1 tumors were PD-L1 positive/CD8 high, group 2 PD-L1 negative/CD8 low, group 3 PD-L1 positive/CD8 low and group 4 PD-L1 negative/CD8 high.

Results Combined PD-L1/CD8 expression was significantly associated with tumor histology (p=0.01). Group 1 tumors were mostly of endometrioid type (71.4%), while group 2 and group 3 tumors were mainly non-endometrioid carcinomas (64.7% and 69.7%, respectively). In group 4, there were nearly equal percentages of endometrioid and non-endometrioid carcinomas (47.8% and 52.2%, respectively). There was no statistical relationship between each group and the clinicopathological features under evaluation (stage, depth of myometrial invasion, lymph node disease and lymph vascular space invasion). Among the four groups there were significant differences in progression-free survival (p=0.032). Group 4 patients had the longest progression-free survival, whereas group 3 patients the shortest. No statistically significant differences were found regarding overall survival (p=0.336).

Conclusion Combined PD-L1/CD8 expression in grade 3 endometrial carcinomas, revealed distinct groups with significant differences in progression-free survival.

Disclosure This research work was supported by the Onassis Foundation - Scholarship ID: G ZO 001-1/2018-2019.

https://doi.org/10.1136/ijgc-2019-ESGO.698

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.